Aim: To investigate the epidemiology and risk factors of infections (CDI) in patients with inflammatory bowel disease (IBD).
Methods: This is a retrospective study of patients diagnosed with IBD. 1006 charts were screened and 654 patients met the inclusion criteria. Patients were divided into 2 cohorts based on the presence of prior diagnosis of CDI. Statistical analysis with Pearson's chi-squared and two-sample -test was performed.
Results: The incidence of CDI among IBD patients was 6.7%. There was equal prevalence of CDI among Crohn's disease (CD) ( = 21, 49%) and ulcerative colitis (UC) ( = 22, 51%). IBD patients acquired CDI at a mean age of 42.7 years, with 56% of infections acquired in the community and only 28% associated with healthcare. Only 30% of IBD patients with CDI had prior antibiotic use, and 16% had prior steroid use. IBD patients were significantly more likely to require biologic therapy (57% versus 37%, < 0.01) and have extraintestinal manifestations of IBD (43% versus 28%, < 0.02).
Conclusions: IBD patients are more susceptible to CDI at a younger age and often lack traditional risk factors. IBD patients with at least one CDI were more likely to require biologic therapy and had greater rates of extraintestinal manifestations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5646328 | PMC |
| http://dx.doi.org/10.1155/2017/4803262 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Infliximab and adalimumab in the treatment of fistulizing Crohn's disease: a propensity score-matched analysis from the prospective Persistence Australian National IBD Cohort (PANIC4) study.
Am J Gastroenterol
December 2024
Department of Gastroenterology and Hepatology, Concord Repatriation General Hospital, Sydney, Australia.
Background/aims: There are spare data on comparative medication efficacy in fistulizing Crohn's disease (FCD), particularly with immunomodulator co-therapy. Persistence is a unique way to assess real-world outcomes.
Methods: The persistence of all dispensed biological agents were analysed from the Australian Pharmaceutical Benefits Scheme (PBS) registry data 2005-2021 for FCD.
Increased medication utilization precedes incidentally diagnosed inflammatory bowel disease: a multicenter, case-control study.
Am J Gastroenterol
December 2024
Gastroenterology Department, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.
This study investigates whether subclinical inflammation in asymptomatic inflammatory bowel disease (IBD) patients leads to increased medication use. In a multicenter, retrospective analysis of patients diagnosed with incidental ulcerative colitis or Crohn's disease during colorectal cancer screening (2010-2021), medication use was compared with symptomatic patients and healthy non-IBD controls. Asymptomatic patients showed a higher use of cardiovascular, antiparasitic, musculoskeletal, respiratory, and sensory organ medications up to five years before diagnosis.
View Article and Find Full Text PDFDeconditioning in quiescent Crohn's Disease patients with heightened fatigue perception.
J Crohns Colitis
January 2025
Professor of Gastroenterology, Translational Medical Sciences, School of Medicine, Faculty of Medicine and Health Sciences, University of Nottingham; NIHR Nottingham Biomedical Research Centre, Nottingham.
Background & Objective: IBD fatigue aetiology is poorly understood. This study quantified body composition and physical function alongside proton magnetic resonance imaging (1H MRI) and spectroscopy (31P MRS) measures of organ structure and function in quiescent Crohn's Disease patients (CD) and healthy volunteers (HV), to identify a physiological basis for IBD fatigue.
Methods: Body composition was determined using DEXA and 1H MRI.
Temporal trends and patterns for early- and late-onset adult liver cancer incidence vary by race/ethnicity, subsite, and histologic type in the United States from 2000 to 2019.
Cancer Causes Control
January 2025
Epidemiology Department, College of Public Health, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Purpose: To examine incidence trends and patterns for early- and late-onset liver cancer.
Methods: Liver and intrahepatic bile duct (IBD) cancers diagnosed between 2000 and 2019 were acquired from 22 SEER registries. Variables included early-onset (20-49) vs.
The Effect of the Size of Gold Nanoparticle Contrast Agents on CT Imaging of the Gastrointestinal Tract and Inflammatory Bowel Disease.
Bioconjug Chem
January 2025
Biochemistry and Molecular Biophysics, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD). CT imaging with contrast agents is commonly used for visualizing the gastrointestinal (GI) tract in UC patients. Contrast agents that provide enhanced imaging performance are highly valuable in this field.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!